Rachel Cohrs Zhang from Stat News, Sandhya Raman from CQ Roll Call, Riley Griffin from Bloomberg News, and Sarah Varney from KFF Health News dive into Trump’s controversial health nominations, including Robert F. Kennedy Jr. and Mehmet Oz. They discuss the implications for Medicare, the potential shifts in health policy, and the urgency of legislative actions before Congress. Additionally, Varney reveals the trials in Idaho challenging strict abortion laws, highlighting the personal struggles faced by women affected by these regulations.

Rachel Cohrs Zhang, Chief Washington correspondent for STAT News, dives into the intricate issues plaguing the health insurance landscape, especially after recent tragedies in the sector. She discusses Congress's efforts to fix a system perceived as broken, highlighting key topics like Medicare improvements and the urgent need for bipartisan health insurance reforms. Cohrs also addresses disparities in healthcare access across the U.S. and the complexities faced by small pharmacies amidst rising pricing pressures from pharmacy benefit managers.

Rachel Cohrs Zhang, chief Washington correspondent for STAT, talks about the recent pharmaceutical negotiations with Medicare, highlighting significant discounts and the industry's reactions. Meghana Keshavan dives into the world of psychedelics, discussing the troubling retraction of three pivotal research papers and FDA setbacks for notable therapies. They explore the ethical implications of these developments and the future of psychedelic treatments in mental health, emphasizing the implications for regulatory integrity and research credibility.

Guests Brittany Trang and Rachel Cohrs Zhang discuss AI in drug development, Medicare coverage for GLP-1 drugs, H5N1 bird flu outbreak, and proposals for obesity drug coverage in Washington, with insights on the first presidential debate's healthcare topics.

STAT's Rachel Cohrs Zhang discusses BIO layoffs and industry changes, while Eric Boodman explores coercion of Black women with sickle cell disease into sterilization. Topics include BioTech's management shake-up, clinical trial diversity consulting, upcoming legislative initiatives, and the importance of informed consent in healthcare.